SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth, product launches, and strategic partnerships, which are expected to drive future expansion. The Q&A session reveals a conservative guidance increase, but potential upside from new products and partnerships. Although some uncertainties remain, such as specific 2027 growth rates and financial impacts, the overall sentiment is positive due to strong margins, increased reimbursement, and international growth potential.
Key Financial Performance
Worldwide Revenue $52.6 million, representing over 11% growth year-over-year. Growth attributed to expanding adoption of the portfolio by a record number of physicians across all sites of service.
U.S. Revenue $49.3 million, reflecting approximately 10% growth year-over-year. Growth was impacted by weather-related disruptions early in the quarter and deliberate pacing of trauma distributor onboarding.
International Revenue $3.3 million, representing an impressive 34% growth year-over-year. Growth driven by accelerating demand for iFuse-TORQ across Europe and Australia.
Gross Profit $41.9 million, an increase of $4.2 million or 11.3% year-over-year. Gross margin for the quarter was flat at 79.8%, supported by favorable procedure mix and operational efficiency initiatives.
Operating Expenses $47 million, representing 4.1% growth year-over-year. Increase driven by higher commissions tied to revenue growth and targeted investments in training, marketing, and product pipeline.
Net Loss $4.3 million or $0.10 per diluted share, compared to a net loss of $6.5 million or $0.15 per diluted share in the prior year. Improvement attributed to strong revenue growth and operating discipline.
Adjusted EBITDA $2.5 million, representing over 440% improvement compared to $0.5 million in the first quarter of 2025. Improvement driven by expanding profitability and prioritization of investments in innovation and commercial expansion.
Free Cash Flow Negative $3.4 million, representing a 50.7% improvement compared to the prior year period. Improvement reflects seasonal impacts and disciplined cash usage.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
INTRA Ti launch: Launched in Q1 2026, expanding the SI joint portfolio and targeting interventional segments with a solution aligned with physician workflow.
TNT TORQ introduction in Europe: Expanded the pelvic trauma portfolio, building on the success of TORQ.
TORQ launch in Australia: Extended leadership in SI joint fusion and established a presence in pelvic fixation.
Granite technology: Reaffirmed superiority with the PALLAS study, showing no breakage or pull-out and significant improvements in pain and disability scores.
International revenue growth: Achieved 33.9% growth, driven by demand for iFuse-TORQ in Europe and Australia.
Smith+Nephew partnership: Broadened access to trauma markets while focusing the direct team on spine and interventional segments.
Revenue growth: Worldwide revenue reached $52.6 million, an 11.2% increase, with U.S. revenue at $49.3 million (10% growth) and international revenue at $3.3 million (33.9% growth).
Operating expenses: Grew by 4.1%, significantly below revenue growth, demonstrating operational efficiency.
Gross margin: Maintained at 79.8%, supported by favorable procedure mix and operational efficiency initiatives.
CMS reimbursement proposal: Proposed new DRG families for complex spinal fusion procedures incorporating Granite, potentially increasing hospital payments by up to $50,000 per procedure.
Expansion into high-value clinical adjacencies: Focused on musculoskeletal care for patients with compromised bone, leveraging biomechanical leadership.
Pipeline advancement: Third breakthrough device on track for a Q3 2026 510(k) submission and commercial launch, expected to expand the addressable market and drive revenue.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Weather-related disruptions: The company experienced weather-related disruptions early in the quarter, which modestly impacted revenue performance.
Trauma distributor onboarding: The decision to deliberately pace trauma distributor onboarding while finalizing the Smith+Nephew partnership caused some impact on revenue momentum.
Cash flow variability: Higher-than-normal cash flow variability is expected in the second and third quarters due to timing of payments for the new headquarters build-out and tenant improvement allowance reimbursements.
Regulatory and reimbursement risks: The company is awaiting finalization of a CMS reimbursement proposal, which, if not approved as proposed, could impact the adoption and economic attractiveness of the Granite technology.
Market competition: The company operates in a competitive market, particularly in the spinal pelvic and pelvic trauma segments, which could impact its ability to maintain or grow its market share.
Operational scaling: The company is expanding to approximately 100 territories over the next 12 months, which could pose challenges in maintaining operational efficiency and profitability during rapid scaling.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company has increased its full-year revenue guidance to a range of $230 million to $233 million, implying year-over-year growth of approximately 14% to 16%. Quarterly year-over-year revenue growth is expected to accelerate as the year progresses.
Gross Margin Expectations: Annual gross margin expectations have been raised to approximately 79%, up 100 basis points from prior guidance, reflecting favorable procedure mix and sustained operational efficiency.
Operating Expenses: Full-year operating expenses are expected to grow approximately 12.5% at the midpoint of revenue guidance, with disciplined investment aimed at strengthening competitive position and facilitating sustained long-term growth.
Spinal Pelvic Fusion Market: The company expects spinal pelvic fusion to become its largest revenue contributor in the coming years, driven by the success of Granite and future platform technologies. The market is supported by favorable reimbursement dynamics and increasing demand for procedures addressing bone-compromising conditions.
Pelvic Trauma Market: The pelvic trauma market is expected to be an attractive contributor to global growth, supported by the iFuse-TORQ TNT system and strategic partnership with Smith+Nephew. Strong reception in Europe reinforces confidence in this market.
New Product Launches: A third breakthrough device is on track for a commercial launch in the fourth quarter of 2026, targeting a significant unmet need in spine surgery and expected to meaningfully expand the total addressable market and drive new revenue over the next several years.
Commercial Expansion: The company plans to expand to approximately 100 territories over the next 12 months, aligning commercial capacity with its strategy to bring several unique platform technologies to market in the coming years.
Reimbursement Changes: CMS has proposed new DRG families for extensive or complex spinal fusion procedures incorporating Granite, potentially increasing average hospital payments by up to $50,000 per procedure. This change, effective October 1, 2026, is expected to support continued adoption of Granite and ensure long-term access for patients, surgeons, and hospitals.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you quantify the weather impact in the quarter and explain why the guidance was only slightly raised?
A:The weather-related impact in January was approximately $0.5 million, but most of it gets recaptured within about 60 days. The guidance was raised conservatively, with the lower end up by $1.5 million and the upper end by $0.5 million, reflecting a disciplined approach early in the year. Potential upside exists from initiatives like the INTRA Ti product expansion, Smith+Nephew partnership, higher DRG reimbursement, and a new product launch in Q4.
Q:Will the new breakthrough device be launched at NASS this year or later?
A:The breakthrough device is expected to be filed in Q3 and launched in Q4. It may not be showcased at NASS this year but will be brought to conferences once cleared. The product addresses a significant unmet clinical need and is expected to increase surgeon density and open new market opportunities.
Q:Can 2027 growth be higher than 2026 growth or exit rate growth?
A:While specific 2027 growth rates were not provided, management highlighted long-term secular tailwinds, including the interventional strategy, Granite scaling, new DRGs, new product launches, Smith+Nephew partnership, and international expansion. These factors suggest potential for continued growth acceleration.
Q:What is the outlook for revenue per rep and its potential cap?
A:Revenue per rep has doubled over the last three years, reaching $2.2 million. This is not considered a cap, as some territories achieve more than double this productivity. The company plans to grow to nearly 100 territories over the next 12 months, leveraging the Smith+Nephew partnership and focusing on growth and penetration.
Q:What is the potential of the spinal pelvic fusion market and Granite's contribution?
A:The spinal pelvic fusion market is expected to be a significant growth driver, supported by Granite and the new breakthrough device. Granite is scaling well, and the new DRGs effective in October will support its adoption. The breakthrough device will increase surgeon density and ASPs, addressing unmet clinical needs.
Q:What is the capital spending outlook and its alignment with growth initiatives?
A:Run-rate CapEx for instrument trays is $9-10 million annually, with additional spending for new headquarters construction. Efforts are being made to drive higher utilization of existing surgical capacity and reduce instrument tray costs for new products. The company remains focused on achieving free cash flow breakeven.
Q:How is the Smith+Nephew partnership progressing and its growth contribution?
A:The partnership focuses on Level 1 and Level 2 trauma centers, with TNT and TORQ products being synergistic with Smith+Nephew's portfolio. Training and rollout are expected to be complete by Q2, with revenue contributions starting in H2. The TAM is around 60,000 patients or $300 million annually.
Q:What are the expectations for international growth with TNT and TORQ launches?
A:International growth is tracking well, with TNT and TORQ launched in Europe and Australia. While still a small percentage of the business, these markets are expected to be accretive to worldwide growth. The company is also exploring other international markets for expansion.
Q:What is the path to 100 territories and its importance?
A:The company plans to grow to nearly 100 territories over the next 12 months to support the launch of the new breakthrough device and increase surgeon density. This expansion aligns with the anticipated aggressive innovation cycle over the next five years.
Q:What is driving the strong gross margin performance and ASP assumptions?
A:Gross margins reached nearly 80%, driven by better-than-expected procedure mix and supply chain efficiencies. ASP assumptions remain conservative, with low single-digit declines expected due to fewer implants in interventional and trauma cases. Upside exists from Granite's 4-implant cases and SI joint procedures.
Q:What is the significance of the new DRG proposal for Granite?
A:The new DRG proposal creates a family for complex spine surgeries, with Granite being one of only two technologies automatically mapping to it. This could increase hospital payments by up to $50,000 per case, supporting Granite's adoption as the standard of care and removing cost objections.
Q:Review of Unclear Management Responses
A:Management avoided providing specific growth rates for 2027, details on Granite's current revenue contribution, and specific Q2 revenue trends. They also did not disclose the exact financial impact of the Smith+Nephew partnership or the new DRG proposal, citing the need for further development and execution.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASC
Anshul
Australia
DRGs
INTRA Ti
SI fusion
SmithNephew
TNT Europe
activity
benefit reimbursement
bone technology
complexity
confidence progress
conviction
cost
density bone
discipline leverage
disease state
field
fixation fusion
focus technology
increase margin
indication
leader
life
manager territory
market contributor
market development
mix efficiency
patient bone
physician engagement
platform technology
sacroiliac
sale model
segment
severity
site care
study
surgeon workflow
trajectory
SIBN Transcript
SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights strong revenue growth, product launches, and strategic partnerships, which are expected to drive future expansion. The Q&A session reveals a conservative guidance increase, but potential upside from new products and partnerships. Although some uncertainties remain, such as specific 2027 growth rates and financial impacts, the overall sentiment is positive due to strong margins, increased reimbursement, and international growth potential.
SI-BONE, Inc. (SIBN) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call highlights strong growth prospects with updated revenue guidance, new product launches, and international expansion plans. The partnership with Smith & Nephew and positive clinical data further support market development. Despite a slight EBITDA miss and gross margin compression, the optimistic guidance and strategic initiatives indicate a positive outlook. The Q&A session did not reveal major concerns, and the market strategy seems solid, suggesting a positive stock price movement in the near term.
SI-BONE, Inc. (SIBN) Q3 2025 Earnings Call Transcript
Positive11-10
The company raised its guidance midpoint due to strong Q3 performance and expects continued positive momentum in Q4. They achieved positive cash flow from operating activities and have a strong product pipeline with international growth prospects. Gross margins exceeded expectations, and they anticipate further improvement. Despite some vague responses, the overall sentiment from the Q&A is positive, with strong growth drivers and strategic initiatives in place.
SIBN Slides
SI-BONE Q1 2026 slides: profitability surges, physician base expands2026-05-11
SI-BONE Q4 2025 slides: profitability milestone as revenue tops $200M2026-02-23
SI-BONE Q2 2025 slides: Revenue jumps 22%, raises full-year guidance2025-08-04
Si-Bone Q1 2025 slides: revenue jumps 25%, achieves positive EBITDA2025-05-05
SIBN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
